In a regulatory filing, Immunovant disclosed that its CEO Peter Salzmann sold 103K shares of common stock on August 14th in a total transaction size of $2.2M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMVT:
- Immunovant price target raised to $33 from $28 at Citi
- Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
- Immunovant reports Q1 EPS (57c), consensus (45c)
- Citi opens ‘positive catalyst watch’ on Immunovant into data
- Immunovant price target raised to $33 from $27 at Wells Fargo